KAHOUNOVA, Zuzana, Daniela KURFURSTOVA, Jan BOUCHAL, Gvantsa KHARAISHVILI, Jiri NAVRATIL, Ján REMŠÍK, Šárka ŠIMEČKOVÁ, Vladimír ŠTUDENT, Alois KOZUBÍK a Karel SOUČEK. The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition. Cytometry Part A. Hoboken: Wiley, 2018, roč. 93A, č. 9, s. 941-951. ISSN 1552-4922. Dostupné z: https://dx.doi.org/10.1002/cyto.a.23101.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název The fibroblast surface markers FAP, anti-fibroblast, and FSP are expressed by cells of epithelial origin and may be altered during epithelial-to-mesenchymal transition
Autoři KAHOUNOVA, Zuzana, Daniela KURFURSTOVA, Jan BOUCHAL, Gvantsa KHARAISHVILI, Jiri NAVRATIL, Ján REMŠÍK (703 Slovensko, domácí), Šárka ŠIMEČKOVÁ (203 Česká republika, domácí), Vladimír ŠTUDENT (203 Česká republika), Alois KOZUBÍK (203 Česká republika, domácí) a Karel SOUČEK (203 Česká republika, domácí).
Vydání Cytometry Part A, Hoboken, Wiley, 2018, 1552-4922.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 10608 Biochemistry and molecular biology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW Full Text
Impakt faktor Impact factor: 3.433
Kód RIV RIV/00216224:14310/18:00107868
Organizační jednotka Přírodovědecká fakulta
Doi http://dx.doi.org/10.1002/cyto.a.23101
UT WoS 000445603300008
Klíčová slova anglicky fibroblast activation protein; fibroblast surface protein; anti-fibroblast; epithelial-to-mesenchymal transition; cancer-associated fibroblasts
Štítky rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Marie Šípková, DiS., učo 437722. Změněno: 29. 4. 2020 11:25.
Anotace
The identification of fibroblasts and cancer-associated fibroblasts from human cancer tissue using surface markers is difficult, especially because the markers used currently are usually not expressed solely by fibroblasts, and the identification of fibroblast-specific surface molecules is still under investigation. It was aimed to compare three commercially available antibodies in the detection of different surface epitopes of fibroblasts (anti-fibroblast, fibroblast activation protein , and fibroblast surface protein). The specificity of their expression, employing fibroblast cell lines and tumor-derived fibroblasts from breast and prostate tissues was investigated. Both the established fibroblast cell line HFF-1 and ex vivo primary fibroblasts isolated from breast and prostate cancer tissues expressed the tested surface markers to different degrees. Surprisingly, those markers were expressed also by permanent cell lines of epithelial origin, both benign and cancer-derived (breast-cell lines MCF 10A, HMLE and prostate-cell lines BPH-1, DU 145, and PC-3). The expression of fibroblast activation protein increased on the surface of previously described models of epithelial cells undergoing epithelial-to-mesenchymal transition in response to treatment with TGF-1. To prove the co-expression of the fibroblast markers on cells of epithelial origin, we used freshly dissociated human prostate and breast cancer tissues. The results confirmed the co-expression of anti-fibroblast and fibroblast surface protein on CD31/CD45-negative/EpCAM-positive epithelial cells. In summary, our data support the findings that the tested fibroblast markers are not fibroblast specific and may be expressed also by cells of epithelial origin (e.g., cells undergoing EMT). Therefore, the expression of these markers should be interpreted with caution, and the combination of several epitopes for both positive (anti-fibroblast or fibroblast activation protein ) and negative (EpCAM) identification of fibroblasts from breast and prostate tumor tissues is advised.
Návaznosti
EE2.3.20.0003, projekt VaVNázev: Algebraické metody v geometrii s potenciálem k aplikacím
GA15-11707S, projekt VaVNázev: Centrosomální abnormality u lidských pluripotentních kmenových buněk.
Investor: Grantová agentura ČR, Centrosomální abnormality u lidských pluripotentních kmenových buněk
NV15-33999A, projekt VaVNázev: Vývoj nových nízkomolekulárních protinádorových léčiv na principu syntetické letality
VytisknoutZobrazeno: 12. 5. 2024 20:50